Nanoemulsion Improves the Neuroprotective Effects of Curcumin in an Experimental Model of Parkinson's Disease

Overview

Journal Neurotox Res

Publisher Springer

Specialty Neurology

Date 2021 Apr 16

PMID 33860897

Citations 16

Authors

Osmar Vieira Ramires Junior

Barbara da Silva Alves

Paula Alice Bezerra Barros

Jamile Lima Rodrigues

Shana Pires Ferreira

Linda Karolynne Seregni Monteiro

Gabriela de Moraes Soares Araujo

Sara Silva Fernandes

Gustavo Richter Vaz

Cristiana Lima Dora

Mariana Appel Hort

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction. Recent studies have shown that curcumin (CUR) has neuroprotective effects in PD experimental models. However, its efficacy is limited due to low water solubility, bioavailability, and access to the central nervous system. In this study, we compared the effects of new curcumin-loaded nanoemulsions (NC) and free CUR in an experimental model of PD. Adult Swiss mice received NC or CUR (25 and 50 mg/kg) or vehicle orally for 30 days. Starting on the eighth day, they were administered rotenone (1 mg/kg) intraperitoneally until the 30th day. At the end of the treatment, motor assessment was evaluated by open field, pole test, and beam walking tests. Oxidative stress markers and mitochondrial complex I activity were measured in the brain tissue. Both NC and CUR treatment significantly improved motor impairment, reduced lipoperoxidation, modified antioxidant defenses, and prevented inhibition of complex I. However, NC was more effective in preventing motor impairment and inhibition of complex I when compared to CUR in the free form. In conclusion, our results suggest that NC effectively enhances the neuroprotective potential of CUR and is a promising nanomedical application for PD.

Citing Articles

Nanotechnology in Parkinson's Disease: overcoming drug delivery challenges and enhancing therapeutic outcomes.

Ali I, Adil M, Imran M, Qureshi S, Qureshi S, Hasan N Drug Deliv Transl Res. 2025; .

PMID: 39878857 DOI: 10.1007/s13346-025-01799-8.

Nasal Delivery to the Brain: Harnessing Nanoparticles for Effective Drug Transport.

Gandhi S, Shastri D, Shah J, Nair A, Jacob S Pharmaceutics. 2024; 16(4).

PMID: 38675142 PMC: 11055100. DOI: 10.3390/pharmaceutics16040481.

Neuroprotective effect of Withania somnifera leaves extract nanoemulsion against penconazole-induced neurotoxicity in albino rats via modulating TGF-β1/Smad2 signaling pathway.

Abomosallam M, Hendam B, Abdallah A, Refaat R, El-Hak H Inflammopharmacology. 2024; 32(3):1903-1928.

PMID: 38630361 PMC: 11136823. DOI: 10.1007/s10787-024-01461-8.

Preparation and Evaluation of Curcumin Derivatives Nanoemulsion Based on Turmeric Extract and Its Antidepressant Effect.

Sheng L, Wei Y, Pi C, Cheng J, Su Z, Wang Y Int J Nanomedicine. 2024; 18:7965-7983.

PMID: 38162571 PMC: 10757808. DOI: 10.2147/IJN.S430769.

Nanophytomedicines as Therapeutic Agents for Parkinson's Disease.

Burns J, Buck A, D Souza S, Dube A, Bardien S ACS Omega. 2023; 8(45):42045-42061.

PMID: 38024675 PMC: 10652730. DOI: 10.1021/acsomega.3c04862.

References

Abbaoui A, Chatoui H, El Hiba O, Gamrani H . Neuroprotective effect of curcumin-I in copper-induced dopaminergic neurotoxicity in rats: A possible link with Parkinson's disease. Neurosci Lett. 2017; 660:103-108. DOI: 10.1016/j.neulet.2017.09.032. View

AEBI H, Wyss S, Scherz B, Skvaril F . Heterogeneity of erythrocyte catalase II. Isolation and characterization of normal and variant erythrocyte catalase and their subunits. Eur J Biochem. 1974; 48(1):137-45. DOI: 10.1111/j.1432-1033.1974.tb03751.x. View

Bagheri H, Ghasemi F, Barreto G, Rafiee R, Sathyapalan T, Sahebkar A . Effects of curcumin on mitochondria in neurodegenerative diseases. Biofactors. 2019; 46(1):5-20. DOI: 10.1002/biof.1566. View

Betzer O, Shilo M, Opochinsky R, Barnoy E, Motiei M, Okun E . The effect of nanoparticle size on the ability to cross the blood-brain barrier: an in vivo study. Nanomedicine (Lond). 2017; 12(13):1533-1546. DOI: 10.2217/nnm-2017-0022. View

Bollimpelli V, Kumar P, Kumari S, Kondapi A . Neuroprotective effect of curcumin-loaded lactoferrin nano particles against rotenone induced neurotoxicity. Neurochem Int. 2016; 95:37-45. DOI: 10.1016/j.neuint.2016.01.006. View

Cannon J, Tapias V, Na H, Honick A, Drolet R, Greenamyre J . A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis. 2009; 34(2):279-90. PMC: 2757935. DOI: 10.1016/j.nbd.2009.01.016. View

Carlberg I, Mannervik B . Glutathione reductase. Methods Enzymol. 1985; 113:484-90. DOI: 10.1016/s0076-6879(85)13062-4. View

Cassina A, Radi R . Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch Biochem Biophys. 1996; 328(2):309-16. DOI: 10.1006/abbi.1996.0178. View

Chakraborty S, Karmenyan A, Tsai J, Chiou A . Inhibitory effects of curcumin and cyclocurcumin in 1-methyl-4-phenylpyridinium (MPP) induced neurotoxicity in differentiated PC12 cells. Sci Rep. 2017; 7(1):16977. PMC: 5717177. DOI: 10.1038/s41598-017-17268-3. View

10.

Charvin D, Medori R, Hauser R, Rascol O . Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018; 17(11):804-822. DOI: 10.1038/nrd.2018.136. View

11.

Connolly B, Lang A . Pharmacological treatment of Parkinson disease: a review. JAMA. 2014; 311(16):1670-83. DOI: 10.1001/jama.2014.3654. View

12.

Darbinyan L, Hambardzumyan L, Simonyan K, Chavushyan V, Manukyan L, Badalyan S . Protective effects of curcumin against rotenone-induced rat model of Parkinson's disease: in vivo electrophysiological and behavioral study. Metab Brain Dis. 2017; 32(6):1791-1803. DOI: 10.1007/s11011-017-0060-y. View

13.

dordevic S, Cekic N, Savic M, Isailovic T, Randelovic D, Markovic B . Parenteral nanoemulsions as promising carriers for brain delivery of risperidone: Design, characterization and in vivo pharmacokinetic evaluation. Int J Pharm. 2015; 493(1-2):40-54. DOI: 10.1016/j.ijpharm.2015.07.007. View

14.

El-Gamal M, Salama M, Collins-Praino L, Baetu I, Fathalla A, Soliman A . Neurotoxin-Induced Rodent Models of Parkinson's Disease: Benefits and Drawbacks. Neurotox Res. 2021; 39(3):897-923. DOI: 10.1007/s12640-021-00356-8. View

15.

Ellman G . Tissue sulfhydryl groups. Arch Biochem Biophys. 1959; 82(1):70-7. DOI: 10.1016/0003-9861(59)90090-6. View

16.

Emerit J, Edeas M, Bricaire F . Neurodegenerative diseases and oxidative stress. Biomed Pharmacother. 2004; 58(1):39-46. DOI: 10.1016/j.biopha.2003.11.004. View

17.

Fan X, Zhang C, Liu D, Yan J, Liang H . The clinical applications of curcumin: current state and the future. Curr Pharm Des. 2012; 19(11):2011-31. View

18.

Finkel T, Holbrook N . Oxidants, oxidative stress and the biology of ageing. Nature. 2000; 408(6809):239-47. DOI: 10.1038/35041687. View

19.

Ganta S, Deshpande D, Korde A, Amiji M . A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol. 2010; 27(7):260-73. DOI: 10.3109/09687688.2010.497971. View

20.

Gao K, Jiang X . Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm. 2006; 310(1-2):213-9. DOI: 10.1016/j.ijpharm.2005.11.040. View